Captopril - Pharmacology
Research News and Information

Sunday, November 22, 2009

Effects of microinjection of angiotensin II and captopril to VTA on morphine self-administration in rats.

30 Aug 2009 The dopaminergic mesolimbic system is considered to be crucial in rewarding actions of opiates. Recent studies have suggested probable interaction between the renin-angiotensin and mesolimbic dopaminergic systems. The present study was undertaken to ... Read more...

Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.

15 Aug 2009 VSMCs respond to changes in the local environment by adjusting their phenotype from contractile to synthetic, a phenomenon known as phenotypic modulation or switching. Failure of VSMCs to acquire and maintain the contractile phenotype plays a key ... Read more...

Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension.

30 Jul 2009 OBJECTIVES: The effects of indapamide, a thiazide-like diuretic, and captopril, an angiotensin-converting enzyme inhibitor, on spontaneous hypertension and the development of left ventricular hypertrophy (LVH), nitric oxide generation and oxidant ... Read more...

Latest indexed articles for 'Captopril - Pharmacology'

These are the very latest articles for this heading:

• Effects of microinjection of angiotensin II and captopril to VTA on morphine self-administration in rats. 30 Aug 2009
• Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. 15 Aug 2009
• Comparison of the effects of indapamide and captopril on the development of spontaneous hypertension. 30 Jul 2009
• Combinational chelation therapy abrogates lead-induced neurodegeneration in rats. 8 Jul 2009
• The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. 2 Jun 2009
• Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. 21 May 2009
• Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. 20 May 2009
• ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat. 29 Apr 2009
• Effect of sodium houttuyfonate on myocardial hypertrophy in mice and rats. 29 Apr 2009
• Effects of microinjection of angiotensin II and captopril into nucleus accumbens on morphine self-administration in rats. 29 Apr 2009
• Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. 11 Apr 2009
• Involvement of central angiotensin II type 1 receptors in LPS-induced systemic vasopressin release and blood pressure regulation in rats. 7 Apr 2009
• Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. 30 Mar 2009
• Ginkgo biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells. 30 Mar 2009
• Effects of sodium depletion on detection thresholds for salty taste in rats. 29 Mar 2009
• Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus. 27 Feb 2009
• Lack of interaction between the peptidomimetic substrates captopril and cephradine. 27 Feb 2009
• Study of the acute cardiovascular effects of several antihypertensive agents with the measurement of plasma catecholamines in mice. 19 Feb 2009
• Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin. 18 Feb 2009
• Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. 30 Jan 2009

See a longer list of these articles.

Technical information about 'Captopril'

Definition: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.

Chemical name: L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-

Registry Number: 62571-86-2

Descriptor UI: D002216

Alternative terms: Captopril; (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; SQ-14,534; SQ 14,534; SQ14,534; SQ-14534; SQ 14534; SQ14534; SQ-14,225; SQ 14,225; SQ14,225; SQ-14225; SQ 14225; SQ14225; Capoten; Lopirin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;

Tree Number: D12.125.072.401.623.270;

Online Note: use CAPTOPRIL to search SQ 14225 1980-93

History Note: 86(80); was see under PROLINE 1980-85; SQ 14225 was see CAPTOPRIL 1980-93